Immunization News and Research

RSS

Large Canadian study suggests COVID-19 mRNA vaccines are safe to use in pregnancy

COVID-19 mRNA vaccines are safe to use in pregnancy and pregnant women experienced lower rates of health events post vaccination than similarly aged, non-pregnant vaccinated people, suggests a large Canadian study published in The Lancet Infectious Diseases journal.

11 Aug 2022

Assessment of replicon ribonucleic acid COVID-19 vaccine in nonhuman primates

Researchers explored the immunogenicity of a replicon ribonucleic acid (repRNA) COVID-19 vaccine, repRNA-CoV2S, in pigtail macaques.

11 Aug 2022

Coronavirus biology: viral RNA synthesis, origin, and vaccines

Researchers analyzed the characteristics of coronaviruses and novel CoV vaccine candidates.

10 Aug 2022

Study evaluates two immunization schedules for the inactivated SARS-CoV-2 vaccine Coronavac

Researchers conducted phase 3 evaluations of the immunogenicity of the two immunization timeframes of the CoronaVac COVID-19 vaccine among Chilean adults.

10 Aug 2022

A novel 3D-printed lab-on-a-chip device concurrently detects SARS-CoV-2 nucleic acid and anti-SARS-CoV-2 antibodies in saliva

Researchers described the development and applications of a 3D-printed lab-on-a-chip device that quickly detected the presence of SARS-CoV-2 in patient's saliva.

10 Aug 2022

CDC and Task Force for Global Health to co-host 11th International Conference on Emerging Infectious Diseases

The Centers for Disease Control and Prevention and the Task Force for Global Health will co-host in person the 11th International Conference on Emerging Infectious Diseases August 7-10, 2022, at the Hyatt Regency Atlanta hotel in Atlanta, GA.

9 Aug 2022

How does the interval between the 1st and 2nd BNT162b2 doses impact the neutralization breadth and potency against variants of concern?

Scientists explored the influence of SARS-CoV-2 extended gap vaccination on the variants of concern neutralization.

9 Aug 2022

Study tests equine polyclonal antibodies against SARS-CoV-2 variants

A recent study published tested equine polyclonal antibodies against SARS-CoV-2.

8 Aug 2022

What is the vaccine effectiveness of BNT162b2 against Omicron in five to 11-year-olds?

Researchers evaluated the effectiveness of the BNT162b2 vaccine against the new SARS-CoV-2 variant of concern, Omicron, in five to 11-year-old children of Ontario, Canada.

8 Aug 2022

Assessing immunization capacity of vaccine platforms with DNA origami harboring SARS-CoV-2 receptor binding domain

Researchers demonstrated that vaccine frameworks containing deoxyribonucleic acid (DNA) origami possessing SARS-CoV-2 receptor-binding domain induce strong protective immunity.

8 Aug 2022

What is the severity of SARS-CoV-2 Omicron BA.4 and BA.5 variant infections in relation to BA.2 infections?

Researchers compared clinical outcomes of COVID-19 cases due to SARS-CoV-2 Omicron BA.2 and Omicron BA.4/BA.5 variants based on the Kaiser Permanente Southern California (KPSC) health records between April 29 and July 2, 2022.

4 Aug 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

Adults aged ≥50 years boosted with SARS-CoV-2 mRNA vaccines less likely to experience adverse reactions after second booster than during initial booster

A new study monitored the safety of the second booster dose of SARS-CoV-2 messenger ribonucleic acid vaccination among those ≥50 Years.

2 Aug 2022

What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations?

In a new study, scientists compared the effectiveness of the SARS-CoV-2 BNT162b2 and mRNA-1273 vaccines booster doses in England.

2 Aug 2022

mRNA vaccines induce faster antibody response against infectious diseases

A new study describes that mRNA vaccines induce antigen-specific antibody response within a very short period of time after immunization.

2 Aug 2022

CDC study describes safety profile of second mRNA COVID booster

The CDC investigates the safety profile of a fourth dose of mRNA-based COVID-19 vaccines in people aged 50 years and older.

1 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

SARS-CoV-2 spike subunit 2–targeted vaccine could more effectively combat all human coronaviruses

In a new study, researchers evidenced that the S2 subunit of SARS-CoV-2 spike (S) could be an integral component of a pan-coronavirus vaccine.

29 Jul 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

Immunization News and Research

Large Canadian study suggests COVID-19 mRNA vaccines are safe to use in pregnancy

Assessment of replicon ribonucleic acid COVID-19 vaccine in nonhuman primates

Coronavirus biology: viral RNA synthesis, origin, and vaccines

Study evaluates two immunization schedules for the inactivated SARS-CoV-2 vaccine Coronavac

A novel 3D-printed lab-on-a-chip device concurrently detects SARS-CoV-2 nucleic acid and anti-SARS-CoV-2 antibodies in saliva

CDC and Task Force for Global Health to co-host 11th International Conference on Emerging Infectious Diseases

How does the interval between the 1st and 2nd BNT162b2 doses impact the neutralization breadth and potency against variants of concern?

Study tests equine polyclonal antibodies against SARS-CoV-2 variants

What is the vaccine effectiveness of BNT162b2 against Omicron in five to 11-year-olds?

Assessing immunization capacity of vaccine platforms with DNA origami harboring SARS-CoV-2 receptor binding domain

What is the severity of SARS-CoV-2 Omicron BA.4 and BA.5 variant infections in relation to BA.2 infections?

A combined influenza and COVID-19 mRNA vaccine

Hybrid immunity retained six months after SARS-CoV-2 exposure

Adults aged ≥50 years boosted with SARS-CoV-2 mRNA vaccines less likely to experience adverse reactions after second booster than during initial booster

What is the efficacy of COVID-19 BNT162b2 and mRNA-1273 booster vaccinations?

mRNA vaccines induce faster antibody response against infectious diseases

CDC study describes safety profile of second mRNA COVID booster

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

SARS-CoV-2 spike subunit 2–targeted vaccine could more effectively combat all human coronaviruses

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News